evaxion-biotech-logo1big.png
Evaxion Biotech to Host Q1 2021 Corporate Update Conference Call & Webcast on May 13
May 06, 2021 07:30 ET | Evaxion Biotech
COPENHAGEN, Denmark, May 06, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to...
evaxion-biotech-logo1big.png
Evaxion Biotech Presents Paper on Potential of Deep Data on Immune Complex Stability to Optimize Cancer Immunotherapy
April 20, 2021 07:30 ET | Evaxion Biotech
COPENHAGEN, Denmark, April 20, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
evaxion-biotech-logo1big.png
Evaxion Biotech Announces Q4 and Full-Year 2020 Financial Results and Provides Business Update
April 06, 2021 07:30 ET | Evaxion Biotech
Successfully completed initial public offering on U.S. Nasdaq in February 2021, raising gross proceeds of $30 millionClinical development on track with dosing of first patient in Phase 1/2a melanoma...
evaxion-biotech-logo1big.png
Evaxion Biotech to Host Full-Year 2020 Corporate Update Conference Call & Webcast on April 6
March 30, 2021 07:30 ET | Evaxion Biotech
COPENHAGEN, Denmark, March 30, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to...
evaxion-biotech-logo1big.png
Evaxion Biotech Announces Publication of Study on S. aureus Bacterium in Scientific Reports
March 16, 2021 07:30 ET | Evaxion Biotech
COPENHAGEN, Denmark, March 16, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to...
evaxion-biotech-logo1big.png
Evaxion Biotech Opens New Office and Laboratories to Support Future Growth
February 16, 2021 07:30 ET | Evaxion Biotech
COPENHAGEN, Denmark, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to...
evaxion-biotech-logo1big.png
Evaxion Biotech Closes its U.S. Initial Public Offering of American Depositary Shares
February 10, 2021 07:30 ET | Evaxion Biotech
COPENHAGEN, Denmark, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of...
evaxion-biotech-logo1big.png
Evaxion Biotech Announces Pricing of Initial Public Offering
February 04, 2021 16:16 ET | Evaxion Biotech
COPENHAGEN, Denmark, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (“Evaxion”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve...
evaxion-biotech-logo1big.png
Evaxion Biotech Announces Filing of Registration Statement in the U.S. for Proposed Initial Public Offering of Securities
January 08, 2021 17:37 ET | Evaxion Biotech
COPENHAGEN, Denmark, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (the “Company” or “Evaxion”), a clinical-stage biotechnology company specializing in the development of AI-driven...
evaxion-biotech-logo1big.png
Evaxion Biotech Doses First Patient in Phase I/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors
December 23, 2020 01:30 ET | Evaxion Biotech
COPENHAGEN, Denmark, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Evaxion Biotech, a clinical-stage biotechnology company developing AI-driven immunotherapies, announces today the dosing of the first patient...